FRA
CRBP icon

Front Row Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Front Row Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10
Closed -$2 – 992
2018
Q2 		$2 Buy
+10
New +$1.82K ﹤0.01% 829

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Front Row Advisors's CRBP Position: Q3 2018 in Review

Front Row Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2018, closing a stake of 10 shares — an estimated $2 sold.

Front Row Advisors first reported a position in CRBP in Q2 2018 and held it in 1 quarter. The position peaked at $2 in Q2 2018. 77 funds tracked by Wall St. Rank hold CRBP as of Q3 2018.

  • Front Row Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Front Row Advisors sold 10 Corbus Pharmaceuticals shares in Q3 2018, an estimated $2.
  • Front Row Advisors first reported a position in Corbus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Front Row Advisors's Corbus Pharmaceuticals position peaked at $2 in Q2 2018.
  • 77 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2018.

Based on Front Row Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.